An experimental drug initially developed to fight cancer cut the risk of death for people hospitalized with Covid by half, according to a study published on Wednesday.
The coronavirus subvariant known as BA.5 accounted for nearly 54% of the country's Covid cases as of Saturday, according to the Centers for Disease Control and Prevention. A similar subvariant, BA.4, makes up 17% more.
A new study published in The Lancet Infectious Diseases found that the clinical profile in recent monkeypox cases is different than in past events, with fatigue and fever less common and genital skin lesions more likely.
Recent Comments